Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

6.4K
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
6.4K
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

2.9K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.9K
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

444
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
444
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

495
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
495

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Role of the serotonin transporter gene in the behavioral expression of autism.

Molecular psychiatry·2001
Same author

Mothers' functioning and children's symptoms 5 years after a SCUD missile attack.

The American journal of psychiatry·2001
Same author

A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder.

The American journal of psychiatry·2001
Same author

3-Carboxamido analogues of morphine and naltrexone. synthesis and opioid receptor binding properties.

Bioorganic & medicinal chemistry letters·2001
Same author

Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization.

The New England journal of medicine·2001
Same author

Effect of eptifibatide on coronary flow reserve following coronary stent implantation (an ESPRIT substudy). Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy.

The American journal of cardiology·2001

Related Experiment Video

Updated: May 5, 2026

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

27.4K

Clinical trials in coronary angiogenesis: issues, problems, consensus: An expert panel summary.

M Simons1, R O Bonow, N A Chronos

  • 1Angiogenesis Research Center, BIDMC, Harvard Medical School, Boston, MA, USA. msimons@caregroup.harvard.edu

Circulation
|September 12, 2000
PubMed
Summary

Therapeutic angiogenesis offers new hope for ischemic heart disease by stimulating blood vessel growth. Experts convened to address key challenges in developing this promising treatment strategy.

More Related Videos

The Aortic Ring Co-culture Assay: A Convenient Tool to Assess the Angiogenic Potential of Mesenchymal Stromal Cells In Vitro
10:04

The Aortic Ring Co-culture Assay: A Convenient Tool to Assess the Angiogenic Potential of Mesenchymal Stromal Cells In Vitro

Published on: September 18, 2017

10.5K
Assessing Therapeutic Angiogenesis in a Murine Model of Hindlimb Ischemia
07:48

Assessing Therapeutic Angiogenesis in a Murine Model of Hindlimb Ischemia

Published on: June 8, 2019

8.2K

Related Experiment Videos

Last Updated: May 5, 2026

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

27.4K
The Aortic Ring Co-culture Assay: A Convenient Tool to Assess the Angiogenic Potential of Mesenchymal Stromal Cells In Vitro
10:04

The Aortic Ring Co-culture Assay: A Convenient Tool to Assess the Angiogenic Potential of Mesenchymal Stromal Cells In Vitro

Published on: September 18, 2017

10.5K
Assessing Therapeutic Angiogenesis in a Murine Model of Hindlimb Ischemia
07:48

Assessing Therapeutic Angiogenesis in a Murine Model of Hindlimb Ischemia

Published on: June 8, 2019

8.2K

Area of Science:

  • Cardiovascular Medicine
  • Regenerative Medicine
  • Biotechnology

Background:

  • Therapeutic angiogenesis using growth factors is a developing treatment for advanced ischemic heart disease.
  • This strategy aims to create new blood supply within the diseased heart.
  • The field is transitioning from preclinical research to clinical applications.

Purpose of the Study:

  • To summarize expert consensus on challenges in therapeutic angiogenesis for coronary disease.
  • To identify key issues for the advancement of clinical trials in this area.
  • To foster a unified approach to developing new treatments for heart disease.

Main Methods:

  • Convened a panel of experts from the Angiogenesis Foundation and Angiogenesis Research Center.
  • Held discussions during the 72nd meeting of the American Heart Association.
  • Focused on defining and reaching consensus on critical development challenges.

Main Results:

  • Identified several unresolved issues in therapeutic angiogenesis.
  • Key challenges include understanding angiogenesis biology, patient selection, and endpoint assessment.
  • Other critical factors are delivery strategy (gene vs. protein), administration route, and side effect profiles.

Conclusions:

  • Consensus was reached on the major challenges facing therapeutic angiogenesis development.
  • Addressing these issues is crucial for successful clinical translation.
  • Further research and collaboration are needed to overcome these hurdles for treating coronary disease.